B Cell Regulation in Autoimmune Diseases

Sokolov, A. V.; Shmidt, A. A.; Lomakin, Yakov A.

doi:10.32607/20758251-2018-10-3-11-22

Cited by 26 publications

(15 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with several reports on the impact of IL-33 in inducing Breg cells in other animal models [17,35]. The beneficial role of Breg cells in suppressing inflammation and limiting the development of autoimmune diseases, including SLE, has been known [17,36,37]. For example, CD1d hi CD5 + Breg cells contributed to the prolonged survival and suppressed lupus progression in NZB/W F1 mice [38].…”

Section: Discussionsupporting

confidence: 90%

Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice

Jaya

Liu

Chan

2020

Cells

View full text Add to dashboard Cite

Interleukin-33 (IL-33), a member of the IL-1 cytokine family, has been recently associated with the development of autoimmune diseases, including systemic lupus erythematosus (SLE). IL-33 is an alarmin and a pleiotropic cytokine that affects various types of immune cells via binding to its receptor, ST2. In this study, we determine the impact of intraperitoneal IL-33 treatments in young lupus, NZB/W F1 mice. Mice were treated from the age of 6 to 11 weeks. We then assessed the proteinuria level, renal damage, survival rate, and anti-dsDNA antibodies. The induction of regulatory B (Breg) cells, changes in the level of autoantibodies, and gene expression were also examined. In comparison to the control group, young NZB/W F1 mice administered with IL-33 had a better survival rate as well as reduced proteinuria level and lupus nephritis. IL-33 treatments significantly increased the level of IgM anti-dsDNA antibodies, IL-10 expressing Breg cells, and alternatively-induced M2 macrophage gene signatures. These results imply that IL-33 exhibits a regulatory role during lupus onset via the expansion of protective IgM anti-dsDNA as well as regulatory cells such as Breg cells and M2 macrophages.

show abstract

Section: Discussionsupporting

confidence: 90%

Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice

Jaya

Liu

Chan

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Recent studies have found that regulatory B (Breg) cells can contribute to the suppression of inflammation and support the differentiation of Tregs ( 24 25 ). IL-10-producing regulatory B (B10) cells, a subset of Breg cells, counteract inflammatory diseases such as collagen-induced arthritis and colitis ( 26 ).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-10-Producing B Cells Help Suppress Ovariectomy-Mediated Osteoporosis

et al. 2020

View full text Add to dashboard Cite

“…IPSE/alpha-1 can induce production of IL-10 in naïve B cells ( 55 ) and stimulate the differentiation of Breg cells ( 56 ) Additionally, B cells bind SEA and internalize it, leading to a 3-fold upregulation in the production of IL-10 ( 55 ). Bregs have been implicated as important players in autoimmunity ( 57 ), and helminth infections have been shown to affect their function in autoimmunity, potentially altering the course of disease ( 58 ). Therefore, stimulation of these cells by S. mansoni products warrants further investigation.…”

Section: Schistosoma Mansonimentioning

confidence: 99%

Clinical Use of Schistosoma mansoni Antigens as Novel Immunotherapies for Autoimmune Disorders

2020

View full text Add to dashboard Cite

The hygiene hypothesis states that improved hygiene and the resulting disappearance of once endemic diseases is at the origin of the enormous increase in immune related disorders such as autoimmune diseases seen in the industrialized world. Helminths, such as Schistosoma mansoni , are thought to provide protection against the development of autoimmune diseases by regulating the host's immune response. This modulation primarily involves induction of regulatory immune responses, such as generation of tolerogenic dendritic cells and alternatively activated macrophages. This points toward the potential of employing helminths or their products/metabolites as therapeutics for autoimmune diseases that are characterized by an excessive inflammatory state, such as multiple sclerosis (MS), type I diabetes (T1D) and inflammatory bowel disease (IBD). In this review, we examine the known mechanisms of immune modulation by S. mansoni , explore preclinical and clinical studies that investigated the use of an array helminthic products in these diseases, and propose that helminthic therapy opens opportunities in the treatment of chronic inflammatory disorders.

show abstract

B Cell Regulation in Autoimmune Diseases

Cited by 26 publications

References 92 publications

Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice

Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice

Interleukin-10-Producing B Cells Help Suppress Ovariectomy-Mediated Osteoporosis

Clinical Use of Schistosoma mansoni Antigens as Novel Immunotherapies for Autoimmune Disorders

Contact Info

Product

Resources

About